Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
The unethical business practices of PBMs have been shown by CMS to increase costs to the government and our nation's health care. It is past time for the PBMs to come into some oversight. Without transparency they pay pharmacies below the cost to dispense, mark it up to charge the government/employer and then charge pharmacies a recover penalty fees (DIR) because the patient did not take their prescription as directed. To date their lobbying efforts have kept them from oversight. Time they are tamed from expensive business practices.